Adrenal gland-dependent augmentation of plasminogen activator inhibitor-1 expression in streptozotocin-induced diabetic mice

Journal of Thrombosis and Haemostasis

Volumn 4, Issue 7, 2006, Pages 1566-1574

  Oishi, K ^a   Ohkura, N ^b   Ishida, Norio ^c  

^a NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY AIST   (Japan)

^b TEIKYO UNIVERSITY   (Japan)

^c UNIVERSITY OF TSUKUBA   (Japan)

Author keywords

Adrenalectomy; Diabetes; Glucocorticoid; Plasminogen activator inhibitor 1; RU486; Streptozotocin

Indexed keywords

CORTICOSTERONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ANTAGONIST; GLUCOSE; INSULIN; MESSENGER RNA; MIFEPRISTONE; PLASMINOGEN ACTIVATOR INHIBITOR 1;

ADRENAL GLAND; ADRENALECTOMY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; GLUCOSE BLOOD LEVEL; HEART; INSULIN BLOOD LEVEL; LUNG; MALE; MOUSE; NONHUMAN; NORTHERN BLOTTING; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; STREPTOZOCIN DIABETES; THROMBOSIS; TISSUE DISTRIBUTION;

ADRENAL GLANDS; ANIMALS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC ANGIOPATHIES; GLUCOCORTICOIDS; LUNG; MICE; MYOCARDIUM; PLASMINOGEN ACTIVATOR INHIBITOR 1; RNA, MESSENGER; STREPTOZOCIN; THROMBOSIS; UP-REGULATION;

EID: 33745237173     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2006.01980.x     Document Type: Article

References (69)

1. Nesto RW. Correlation between cardiovascular disease and diabetes mellitus: Current concepts. Am J Med 2004; 116: 11S-22S.
2. Aronson D. Impaired modulation of circadian rhythms in patients with diabetes mellitus: A risk factor for cardiac thrombotic events? Chronobiol Int 2001; 18: 109-21.
3. Haffner SM. Insulin resistance, inflammation, and the prediabetic state. Am J Cardiol 2003; 92: 18J-26J.
4. Tsikouris JP, Suarez JA, Meyerrose GE. Plasminogen activator inhibitor-1: Physiologic role, regulation, and the influence of common pharmacologic agents. J Clin Pharmacol 2002; 42: 1187-99.
5. Yamamoto K, Saito H. A pathological role of increased expression of plasminogen activator inhibitor-1 in human or animal disorders. Int J Hematol 1998; 68: 371-85.
6. Vague P, Juhan-Vague I. Fibrinogen, fibrinolysis and diabetes mellitus: a comment. Diabetologia 1997; 40: 738-40.
7. McGill JB, Schneider DJ, Arfken CL, Lucore CL, Sobel BE. Factors responsible for impaired fibrinolysis in obese subjects and NIDDM patients. Diabetes 1994; 43: 104-9.
8. Gruden G, Cavallo-Perin P, Bazzan M, Stella S, Vuolo A, Pagano G. PAI-1 and factor VII activity are higher in IDDM patients with microalbuminuria. Diabetes 1994; 43: 426-9.
9. Garcia Frade LJ, de la Calle H, Torrado MC, Lara JI, Cuellar L, Garcia Avello A. Hypofibrinolysis associated with vasculopathy in non insulin dependent diabetes mellitus. Thromb Res 1990; 59: 51-9.
10. Carmassi F, Morale M, Puccetti R, De Negri F, Monzani F, Navalesi R, Mariani G. Coagulation and fibrinolytic system impairment in insulin dependent diabetes mellitus. Thromb Res 1992; 67: 643-54.
11. Aronson D, Weinrauch LA, D'Elia JA, Tofler GH, Burger AJ. Circadian patterns of heart rate variability, fibrinolytic activity, and hemostatic factors in type I diabetes mellitus with cardiac autonomic neuropathy. Am J Cardiol 1999; 84: 449-53.
12. Auwerx J, Bouillon R, Collen D, Geboers J. Tissue-type plasminogen activator antigen and plasminogen activator inhibitor in diabetes mellitus. Arteriosclerosis 1988; 8: 68-72.
13. Skrha J, Hodinar A, Kvasnicka J, Hilgertova J. Relationship of oxidative stress and fibrinolysis in diabetes mellitus. Diabet Med 1996; 13: 800-5.
14. Hernandez C, Chacon P, Garcia-Pascual L, Mesa J, Simo R. Relationship between lipoprotein(a) phenotypes and plaminogen activator inhibitor type 1 in diabetic patients. Thromb Res 2000; 99: 119-27.
15. Oishi K, Kasamatsu M, Ishida N. Gene- and tissue-specific alterations of circadian clock gene expression in streptozotocin-induced diabetic mice under restricted feeding. Biochem Biophys Res Commun 2004; 317: 330-4.
16. Gai W, Schott-Ohly P, Schulte im Walde S, Gleichmann H. Differential target molecules for toxicity induced by streptozotocin and alloxan in pancreatic islets of mice in vitro. Exp Clin Endocrinol Diabetes 2004; 112: 29-37.
17. Suzuki M, Akimoto K, Hattori Y. Glucose upregulates plasminogen activator inhibitor-1 gene expression in vascular smooth muscle cells. Life Sci 2002; 72: 59-66.
18. Macfelda K, Weiss TW, Kaun C, Breuss JM, Zorn G, Oberndorfer U, Voegele-Kadletz M, Huber-Beckmann R, Ullrich R, Binder BR, Losert UM, Maurer G, Pacher R, Huber K, Wojta J. Plasminogen activator inhibitor 1 expression is regulated by the inflammatory mediators interleukin-1alpha, tumor necrosis factor-alpha, transforming growth factor-beta and oncostatin M in human cardiac myocytes. J Mol Cell Cardiol 2002; 34: 1681-91.
19. Dennler S, Itoh S, Vivien D, ten Dijke P, Huet S, Gauthier JM. Direct binding of Smad3 and Smad4 to critical TGF beta-inducible elements in the promoter of human plasminogen activator inhibitor-type 1 gene. EMBO J 1998; 17: 3091-100.
20. Wilson HM, Reid FJ, Brown PA, Power DA, Haites NE, Booth NA. Effect of transforming growth factor-beta 1 on plasminogen activators and plasminogen activator inhibitor-1 in renal glomerular cells. Exp Nephrol 1993; 1: 343-50.
21. Chen YQ, Sloan-Lancaster J, Berg DT, Richardson MA, Grinnell B, Tseng-Crank J. Differential mechanisms of plasminogen activator inhibitor-1 gene activation by transforming growth factor-beta and tumor necrosis factor-alpha in endothelial cells. Thromb Haemost 2001; 86: 1563-72.
22. Pandey M, Loskutoff DJ, Samad F. Molecular mechanisms of tumor necrosis factor-alpha-mediated plasminogen activator inhibitor-1 expression in adipocytes. FASEB J 2005; 19: 1317-9.
23. Yamamoto Y, Ishizu A, Ikeda H, Otsuka N, Yoshiki T. Dexamethasone increased plasminogen activator inhibitor-1 expression on human umbilical vein endothelial cells: An additive effect to tumor necrosis factor-alpha. Pathobiology 2004; 71: 295-301.
24. Kietzmann T, Samoylenko A, Roth U, Jungermann K. Hypoxia-inducible factor-1 and hypoxia response elements mediate the induction of plasminogen activator inhibitor-1 gene expression by insulin in primary rat hepatocytes. Blood 2003; 101: 907-14.
25. Brown NJ, Agirbasli MA, Williams GH, Litchfield WR, Vaughan DE. Effect of activation and inhibition of the renin-angiotensin system on plasma PAI-1. Hypertension 1998; 32: 965-71.
26. Vaughan DE, Lazos SA, Tong K. Angiotensin II regulates the expression of plasminogen activator inhibitor-1 in cultured endothelial cells. A potential link between the renin-angiotensin system and thrombosis. J Clin Invest 1995; 95: 995-1001.
27. De Taeye B, Smith LH, Vaughan DE. Plasminogen activator inhibitor-1: A common denominator in obesity, diabetes and cardiovascular disease. Curr Opin Pharmacol 2005; 5: 149-54.
28. Andreasen PA, Georg B, Lund LR, Riccio A, Stacey SN. Plasminogen activator inhibitors: Hormonally regulated serpins. Mol Cell Endocrinol 1990; 68: 1-19.
29. Mayer M. Biochemical and biological aspects of the plasminogen activation system. Clin Biochem 1990; 23: 197-211.
30. Bruzdzinski CJ, Johnson MR, Goble CA, Winograd SS, Gelehrter TD. Mechanism of glucocorticoid induction of the rat plasminogen activator inhibitor-1 gene in HTC rat hepatoma cells: Identification of cis-acting regulatory elements. Mol Endocrinol 1993; 7: 1169-77.
31. Udden J, Eriksson P, Hoffstedt J. Glucocorticoid-regulated adipose tissue secretion of PAI-1, but not IL-6, TNFalpha or leptin in vivo. Horm Metab Res 2002; 34: 698-702.
32. Morange PE, Aubert J, Peiretti F, Lijnen HR, Vague P, Verdier M, Negrel R, Juhan-Vague I, Alessi MC. Glucocorticoids and insulin promote plasminogen activator inhibitor 1 production by human adipose tissue. Diabetes 1999; 48: 890-5.
33. Konkle BA, Schuster SJ, Kelly MD, Harjes K, Hassett DE, Bohrer M, Tavassoli M. Plasminogen activator inhibitor-1 messenger RNA expression is induced in rat hepatocytes in vivo by dexamethasone. Blood 1992; 79: 2636-42.
34. Cryer PE. Hierarchy of physiological responses to hypoglycemia: relevance to clinical hypoglycemia in type I (insulin dependent) diabetes mellitus. Horm Metab Res 1997; 29: 92-6.
35. Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 1984; 5: 395-410.
36. Oishi K, Ohkura N, Amagai N, Ishida N. Involvement of circadian clock gene Clock in diabetes-induced circadian augmentation of plasminogen activator inhibitor-1 (PAI-1) expression in the mouse heart. FEBS Lett 2005; 579: 3555-9.
37. Oishi K, Ohkura N, Kasamatsu M, Fukushima N, Shirai H, Matsuda J, Horie S, Ishida N. Tissue-specific augmentation of circadian PAI-1 expression in mice with streptozotocin-induced diabetes. Thromb Res 2004; 114: 129-35.
38. Chan O, Chan S, Inouye K, Vranic M, Matthews SG. Molecular regulation of the hypothalamo-pituitary-adrenal axis in streptozotocin-induced diabetes: Effects of insulin treatment. Endocrinology 2001; 142: 4872-9.
39. Riccio A, Lund LR, Sartorio R, Lania A, Andreasen PA, Dano K, Blasi F. The regulatory region of the human plasminogen activator inhibitor type-1 (PAI-1) gene. Nucleic Acids Res 1988; 16: 2805-24.
40. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, Calles K, Engstrom O, Harlan J, Muchmore S, Ramqvist AK, Thorell S, Ohman L, Greer J, Gustafsson JA, Carlstedt-Duke J, Carlquist M. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003; 278: 22748-54.
41. Yang H, Wright Jr JR. Human beta cells are exceedingly resistant to streptozotocin in vivo. Endocrinology 2002; 143: 2491-5.
42. Babij P, Psaltis G, Song D, Kulik J, Mollova N, Abruzzese RV, Nordstrom JL. 'Blue heart': Characterization of a mifepristone-dependent system for conditional gene expression in genetically modified animals. Biochim Biophys Acta 2003; 1627: 15-25.
43. Jacobson L. Glucocorticoid replacement, but not corticotropin-releasing hormone deficiency, prevents adrenalectomy-induced anorexia in mice. Endocrinology 1999; 140: 310-7.
44. Oishi K, Amagai N, Shirai H, Kadota K, Ohkura N, Ishida N. Genome-wide expression analysis reveals 100 adrenal gland-dependent circadian genes in the mouse liver. DNA Res 2005; 12: 191-202.
45. Ikonomov OC, Stoynev AG, Vrabchev NC, Shisheva AC, Tarkolev NT. Circadian rhythms of food and 1% NaCl intake, urine and electrolyte excretion, plasma renin activity and insulin concentration in adrenalectomized rats. Acta Physiol Hung 1985; 65: 181-98.
46. Cameron OG, Kronfol Z, Greden JF, Carroll BJ. Hypothalamic-pituitary-adrenocortical activity in patients with diabetes mellitus. Arch Gen Psychiatry 1984; 41: 1090-5.
47. Roy M, Collier B, Roy A. Hypothalamic-pituitary-adrenal axis dysregulation among diabetic outpatients. Psychiatry Res 1990; 31: 31-7.
48. Shapiro ET, Polonsky KS, Copinschi G, Bosson D, Tillil H, Blackman J, Lewis G, Van Cauter E. Nocturnal elevation of glucose levels during fasting in noninsulin-dependent diabetes. J Clin Endocrinol Metab 1991; 72: 444-54.
49. Vaughan DE, Declerck PJ, Van Houtte E, De Mol M, Collen D. Studies of recombinant plasminogen activator inhibitor-1 in rabbits. Pharmacokinetics and evidence for reactivation of latent plasminogen activator inhibitor-1 in vivo. Circ Res 1990; 67: 1281-6.
50. Trocki O, Baer DJ, Castonguay TW. Comparison of effects of adrenalectomy and RU-486 in rats given a choice of maintenance diet and fat supplement. Am J Physiol 1995; 269: R708-19.
51. Aso Y, Okumura KI, Yoshida N, Tayama K, Takemura Y, Inukai T. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: Association with a decrease in plasminogen activator inhibitor 1. Exp Clin Endocrinol Diabetes 2004; 112: 175-80.
52. Herlihy OM, Barrow BA, Grant PJ, Levy JC. Hyperglycaemic siblings of Type II (non-insulin-dependent) diabetic patients have increased PAI-1, central obesity and insulin resistance compared with their paired normoglycaemic sibling. Diabetologia 2002; 45: 635-41.
53. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Proinflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004; 53: 2079-86.
54. Jean C, Roy D, Nadeau A. Diminished diabetogenic effect of streptozotocin in adrenodemedullated rats. Can J Physiol Pharmacol 1994; 72: 992-8.
55. Sheppard KE. Corticosteroid receptors, 11 beta-hydroxysteroid dehydrogenase, and the heart. Vitam Horm 2003; 66: 77-112.
56. Healy AM, Gelehrter TD. Induction of plasminogen activator inhibitor-1 in HepG2 human hepatoma cells by mediators of the acute phase response. J Biol Chem 1994; 269: 19095-100.
57. Hopkins WE, Westerhausen Jr DR, Sobel BE, Billadello JJ. Transcriptional regulation of plasminogen activator inhibitor type-1 mRNA in Hep G2 cells by epidermal growth factor. Nucleic Acids Res 1991; 19: 163-8.
58. Olofsson B, Korpelainen E, Pepper MS, Mandriota SJ, Aase K, Kumar V, Gunji Y, Jeltsch MM, Shibuya M, Alitalo K, Eriksson U. Vascular endothelial growth factor B (VEGF-B) binds to VEGF receptor-1 and regulates plasminogen activator activity in endothelial cells. Proc Natl Acad Sci USA 1998; 95: 11709-14.
59. Saksela O, Moscatelli D, Rifkin DB. The opposing effects of basic fibroblast growth factor and transforming growth factor beta on the regulation of plasminogen activator activity in capillary endothelial cells. J Cell Biol 1987; 105: 957-63.
60. Albrecht W, de Gasparo M, Marki F. Role of the adrenals in the development of streptozotocin (STR)-induced diabetes in male albino rats. Horm Metab Res 1984; 16: 71-6.
61. Maiyar AC, Phu PT, Huang AJ, Firestone GL. Repression of glucocorticoid receptor transactivation and DNA binding of a glucocorticoid response element within the serum/glucocorticoid-inducible protein kinase (sgk) gene promoter by the p53 tumor suppressor protein. Mol Endocrinol 1997; 11: 312-29.
62. Webster MK, Goya L, Ge Y, Maiyar AC, Firestone GL. Characterization of sgk, a novel member of the serine/threonine protein kinase gene family which is transcriptionally induced by glucocorticoids and serum. Mol Cell Biol 1993; 13: 2031-40.
63. Sheppard KE, Autelitano DJ. 11Beta-hydroxysteroid dehydrogenase 1 transforms 11-dehydrocorticosterone into transcriptionally active glucocorticoid in neonatal rat heart. Endocrinology 2002; 143: 198-204.
64. Ullrich S, Berchtold S, Ranta F, Seebohm G, Henke G, Lupescu A, Mack AF, Chao CM, Su J, Nitschke R, Alexander D, Friedrich B, Wulff P, Kuhl D, Lang F. Serum- and glucocorticoid-inducible kinase 1 (SGK1) mediates glucocorticoid-induced inhibition of insulin secretion. Diabetes 2005; 54: 1090-9.
65. Wang Q, Zhang X, Wang Y, Deng A, Zhu Z, Feng Y. Significance and expression of serum and glucocorticoid-inducible kinase in kidney of mice with diabetic nephropathy. J Huazhong Univ Sci Technolog Med Sci 2005; 25: 170-3.
66. Maemura K, Layne MD, Watanabe M, Perrell MA, Nagai R, Lee ME. Molecular mechanisms of morning onset of myocardial infarction. Ann N Y Acad Sci 2001; 947: 398-402.
67. Andreotti F, Kluft C. Circadian variation of fibrinolytic activity in blood. Chronobiol Int 1991; 8: 336-51.
68. Maemura K, de la Monte SM, Chin MT, Layne MD, Hsieh CM, Yet SF, Perrella MA, Lee ME. CLIF, a novel cycle-like factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression. J Biol Chem 2000; 275: 36847-51.
69. Reppert SM, Weaver DR. Molecular analysis of mammalian circadian rhythms. Annu Rev Physiol 2001; 63: 647-76.